The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Anti-Rheumatic Drugs Market Research Report 2024
Synopsis
Anti-rheumatic drugs are medications used to treat rheumatic diseases, which are conditions characterized by inflammation, pain, stiffness, and swelling in the joints, muscles, and other connective tissues. Rheumatic diseases encompass a wide range of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), and juvenile idiopathic arthritis, among others. The goals of treatment with anti-rheumatic drugs are to reduce inflammation, alleviate symptoms, prevent disease progression, and improve overall quality of life for patients.
The global Anti-Rheumatic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Anti-Rheumatic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Anti-Rheumatic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Anti-Rheumatic Drugs in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Anti-Rheumatic Drugs include Novartis, UCB, AbbVie, Bristol-Myers Squibb, Merck, HEYL Chemisch-pharmazeutische Fabrik, Roche, Johnson & Johnson, Amgen, Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Anti-Rheumatic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Rheumatic Drugs.
The Anti-Rheumatic Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Rheumatic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Rheumatic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
UCB
AbbVie
Bristol-Myers Squibb
Merck
HEYL Chemisch-pharmazeutische Fabrik
Roche
Johnson & Johnson
Amgen
Pfizer
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Eli Lilly and Company
Celltrion
Astellas Pharma
Simcere
Daiichi Sankyo
Asahi Kasei
Segment by Type
Disease Modifying Anti-rheumatics Drugs (DMARD's)
Nonsteroidal Anti-inflammatory Drugs (NSAID's)
Corticosteroids
Uric Acid Drugs
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Rheumatic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Anti-rheumatic drugs are medications used to treat rheumatic diseases, which are conditions characterized by inflammation, pain, stiffness, and swelling in the joints, muscles, and other connective tissues. Rheumatic diseases encompass a wide range of conditions, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, systemic lupus erythematosus (SLE), and juvenile idiopathic arthritis, among others. The goals of treatment with anti-rheumatic drugs are to reduce inflammation, alleviate symptoms, prevent disease progression, and improve overall quality of life for patients.
The global Anti-Rheumatic Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Anti-Rheumatic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Anti-Rheumatic Drugs is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Anti-Rheumatic Drugs in Hospital Pharmacies is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Anti-Rheumatic Drugs include Novartis, UCB, AbbVie, Bristol-Myers Squibb, Merck, HEYL Chemisch-pharmazeutische Fabrik, Roche, Johnson & Johnson, Amgen, Pfizer, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Anti-Rheumatic Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Rheumatic Drugs.
The Anti-Rheumatic Drugs market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Rheumatic Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Rheumatic Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
UCB
AbbVie
Bristol-Myers Squibb
Merck
HEYL Chemisch-pharmazeutische Fabrik
Roche
Johnson & Johnson
Amgen
Pfizer
GSK
Sanofi
Abbott Laboratories
Teva Pharmaceutical
Eli Lilly and Company
Celltrion
Astellas Pharma
Simcere
Daiichi Sankyo
Asahi Kasei
Segment by Type
Disease Modifying Anti-rheumatics Drugs (DMARD's)
Nonsteroidal Anti-inflammatory Drugs (NSAID's)
Corticosteroids
Uric Acid Drugs
Others
Segment by Application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Rheumatic Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Rheumatic Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Disease Modifying Anti-rheumatics Drugs (DMARD's)
1.2.3 Nonsteroidal Anti-inflammatory Drugs (NSAID's)
1.2.4 Corticosteroids
1.2.5 Uric Acid Drugs
1.2.6 Others
1.3 Market by Application
1.3.1 Global Anti-Rheumatic Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-Rheumatic Drugs Market Perspective (2019-2030)
2.2 Global Anti-Rheumatic Drugs Growth Trends by Region
2.2.1 Global Anti-Rheumatic Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-Rheumatic Drugs Historic Market Size by Region (2019-2024)
2.2.3 Anti-Rheumatic Drugs Forecasted Market Size by Region (2025-2030)
2.3 Anti-Rheumatic Drugs Market Dynamics
2.3.1 Anti-Rheumatic Drugs Industry Trends
2.3.2 Anti-Rheumatic Drugs Market Drivers
2.3.3 Anti-Rheumatic Drugs Market Challenges
2.3.4 Anti-Rheumatic Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-Rheumatic Drugs Players by Revenue
3.1.1 Global Top Anti-Rheumatic Drugs Players by Revenue (2019-2024)
3.1.2 Global Anti-Rheumatic Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Anti-Rheumatic Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Anti-Rheumatic Drugs Revenue
3.4 Global Anti-Rheumatic Drugs Market Concentration Ratio
3.4.1 Global Anti-Rheumatic Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Rheumatic Drugs Revenue in 2023
3.5 Global Key Players of Anti-Rheumatic Drugs Head office and Area Served
3.6 Global Key Players of Anti-Rheumatic Drugs, Product and Application
3.7 Global Key Players of Anti-Rheumatic Drugs, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-Rheumatic Drugs Breakdown Data by Type
4.1 Global Anti-Rheumatic Drugs Historic Market Size by Type (2019-2024)
4.2 Global Anti-Rheumatic Drugs Forecasted Market Size by Type (2025-2030)
5 Anti-Rheumatic Drugs Breakdown Data by Application
5.1 Global Anti-Rheumatic Drugs Historic Market Size by Application (2019-2024)
5.2 Global Anti-Rheumatic Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-Rheumatic Drugs Market Size (2019-2030)
6.2 North America Anti-Rheumatic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-Rheumatic Drugs Market Size by Country (2019-2024)
6.4 North America Anti-Rheumatic Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-Rheumatic Drugs Market Size (2019-2030)
7.2 Europe Anti-Rheumatic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-Rheumatic Drugs Market Size by Country (2019-2024)
7.4 Europe Anti-Rheumatic Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-Rheumatic Drugs Market Size (2019-2030)
8.2 Asia-Pacific Anti-Rheumatic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-Rheumatic Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-Rheumatic Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-Rheumatic Drugs Market Size (2019-2030)
9.2 Latin America Anti-Rheumatic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-Rheumatic Drugs Market Size by Country (2019-2024)
9.4 Latin America Anti-Rheumatic Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-Rheumatic Drugs Market Size (2019-2030)
10.2 Middle East & Africa Anti-Rheumatic Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-Rheumatic Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-Rheumatic Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Novartis
11.1.1 Novartis Company Details
11.1.2 Novartis Business Overview
11.1.3 Novartis Anti-Rheumatic Drugs Introduction
11.1.4 Novartis Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.1.5 Novartis Recent Development
11.2 UCB
11.2.1 UCB Company Details
11.2.2 UCB Business Overview
11.2.3 UCB Anti-Rheumatic Drugs Introduction
11.2.4 UCB Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.2.5 UCB Recent Development
11.3 AbbVie
11.3.1 AbbVie Company Details
11.3.2 AbbVie Business Overview
11.3.3 AbbVie Anti-Rheumatic Drugs Introduction
11.3.4 AbbVie Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.3.5 AbbVie Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Details
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Anti-Rheumatic Drugs Introduction
11.4.4 Bristol-Myers Squibb Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Merck
11.5.1 Merck Company Details
11.5.2 Merck Business Overview
11.5.3 Merck Anti-Rheumatic Drugs Introduction
11.5.4 Merck Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.5.5 Merck Recent Development
11.6 HEYL Chemisch-pharmazeutische Fabrik
11.6.1 HEYL Chemisch-pharmazeutische Fabrik Company Details
11.6.2 HEYL Chemisch-pharmazeutische Fabrik Business Overview
11.6.3 HEYL Chemisch-pharmazeutische Fabrik Anti-Rheumatic Drugs Introduction
11.6.4 HEYL Chemisch-pharmazeutische Fabrik Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.6.5 HEYL Chemisch-pharmazeutische Fabrik Recent Development
11.7 Roche
11.7.1 Roche Company Details
11.7.2 Roche Business Overview
11.7.3 Roche Anti-Rheumatic Drugs Introduction
11.7.4 Roche Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.7.5 Roche Recent Development
11.8 Johnson & Johnson
11.8.1 Johnson & Johnson Company Details
11.8.2 Johnson & Johnson Business Overview
11.8.3 Johnson & Johnson Anti-Rheumatic Drugs Introduction
11.8.4 Johnson & Johnson Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.8.5 Johnson & Johnson Recent Development
11.9 Amgen
11.9.1 Amgen Company Details
11.9.2 Amgen Business Overview
11.9.3 Amgen Anti-Rheumatic Drugs Introduction
11.9.4 Amgen Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.9.5 Amgen Recent Development
11.10 Pfizer
11.10.1 Pfizer Company Details
11.10.2 Pfizer Business Overview
11.10.3 Pfizer Anti-Rheumatic Drugs Introduction
11.10.4 Pfizer Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.10.5 Pfizer Recent Development
11.11 GSK
11.11.1 GSK Company Details
11.11.2 GSK Business Overview
11.11.3 GSK Anti-Rheumatic Drugs Introduction
11.11.4 GSK Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.11.5 GSK Recent Development
11.12 Sanofi
11.12.1 Sanofi Company Details
11.12.2 Sanofi Business Overview
11.12.3 Sanofi Anti-Rheumatic Drugs Introduction
11.12.4 Sanofi Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.12.5 Sanofi Recent Development
11.13 Abbott Laboratories
11.13.1 Abbott Laboratories Company Details
11.13.2 Abbott Laboratories Business Overview
11.13.3 Abbott Laboratories Anti-Rheumatic Drugs Introduction
11.13.4 Abbott Laboratories Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.13.5 Abbott Laboratories Recent Development
11.14 Teva Pharmaceutical
11.14.1 Teva Pharmaceutical Company Details
11.14.2 Teva Pharmaceutical Business Overview
11.14.3 Teva Pharmaceutical Anti-Rheumatic Drugs Introduction
11.14.4 Teva Pharmaceutical Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.14.5 Teva Pharmaceutical Recent Development
11.15 Eli Lilly and Company
11.15.1 Eli Lilly and Company Company Details
11.15.2 Eli Lilly and Company Business Overview
11.15.3 Eli Lilly and Company Anti-Rheumatic Drugs Introduction
11.15.4 Eli Lilly and Company Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.15.5 Eli Lilly and Company Recent Development
11.16 Celltrion
11.16.1 Celltrion Company Details
11.16.2 Celltrion Business Overview
11.16.3 Celltrion Anti-Rheumatic Drugs Introduction
11.16.4 Celltrion Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.16.5 Celltrion Recent Development
11.17 Astellas Pharma
11.17.1 Astellas Pharma Company Details
11.17.2 Astellas Pharma Business Overview
11.17.3 Astellas Pharma Anti-Rheumatic Drugs Introduction
11.17.4 Astellas Pharma Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.17.5 Astellas Pharma Recent Development
11.18 Simcere
11.18.1 Simcere Company Details
11.18.2 Simcere Business Overview
11.18.3 Simcere Anti-Rheumatic Drugs Introduction
11.18.4 Simcere Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.18.5 Simcere Recent Development
11.19 Daiichi Sankyo
11.19.1 Daiichi Sankyo Company Details
11.19.2 Daiichi Sankyo Business Overview
11.19.3 Daiichi Sankyo Anti-Rheumatic Drugs Introduction
11.19.4 Daiichi Sankyo Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.19.5 Daiichi Sankyo Recent Development
11.20 Asahi Kasei
11.20.1 Asahi Kasei Company Details
11.20.2 Asahi Kasei Business Overview
11.20.3 Asahi Kasei Anti-Rheumatic Drugs Introduction
11.20.4 Asahi Kasei Revenue in Anti-Rheumatic Drugs Business (2019-2024)
11.20.5 Asahi Kasei Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Anti-Rheumatic Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Disease Modifying Anti-rheumatics Drugs (DMARD's)
Table 3. Key Players of Nonsteroidal Anti-inflammatory Drugs (NSAID's)
Table 4. Key Players of Corticosteroids
Table 5. Key Players of Uric Acid Drugs
Table 6. Key Players of Others
Table 7. Global Anti-Rheumatic Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Anti-Rheumatic Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 9. Global Anti-Rheumatic Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 10. Global Anti-Rheumatic Drugs Market Share by Region (2019-2024)
Table 11. Global Anti-Rheumatic Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 12. Global Anti-Rheumatic Drugs Market Share by Region (2025-2030)
Table 13. Anti-Rheumatic Drugs Market Trends
Table 14. Anti-Rheumatic Drugs Market Drivers
Table 15. Anti-Rheumatic Drugs Market Challenges
Table 16. Anti-Rheumatic Drugs Market Restraints
Table 17. Global Anti-Rheumatic Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 18. Global Anti-Rheumatic Drugs Market Share by Players (2019-2024)
Table 19. Global Top Anti-Rheumatic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Rheumatic Drugs as of 2023)
Table 20. Ranking of Global Top Anti-Rheumatic Drugs Companies by Revenue (US$ Million) in 2023
Table 21. Global 5 Largest Players Market Share by Anti-Rheumatic Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 22. Global Key Players of Anti-Rheumatic Drugs, Headquarters and Area Served
Table 23. Global Key Players of Anti-Rheumatic Drugs, Product and Application
Table 24. Global Key Players of Anti-Rheumatic Drugs, Date of Enter into This Industry
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Anti-Rheumatic Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 27. Global Anti-Rheumatic Drugs Revenue Market Share by Type (2019-2024)
Table 28. Global Anti-Rheumatic Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 29. Global Anti-Rheumatic Drugs Revenue Market Share by Type (2025-2030)
Table 30. Global Anti-Rheumatic Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 31. Global Anti-Rheumatic Drugs Revenue Market Share by Application (2019-2024)
Table 32. Global Anti-Rheumatic Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 33. Global Anti-Rheumatic Drugs Revenue Market Share by Application (2025-2030)
Table 34. North America Anti-Rheumatic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. North America Anti-Rheumatic Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 36. North America Anti-Rheumatic Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 37. Europe Anti-Rheumatic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Europe Anti-Rheumatic Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 39. Europe Anti-Rheumatic Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 40. Asia-Pacific Anti-Rheumatic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Asia-Pacific Anti-Rheumatic Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 42. Asia-Pacific Anti-Rheumatic Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 43. Latin America Anti-Rheumatic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Latin America Anti-Rheumatic Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 45. Latin America Anti-Rheumatic Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 46. Middle East & Africa Anti-Rheumatic Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 47. Middle East & Africa Anti-Rheumatic Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 48. Middle East & Africa Anti-Rheumatic Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 49. Novartis Company Details
Table 50. Novartis Business Overview
Table 51. Novartis Anti-Rheumatic Drugs Product
Table 52. Novartis Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 53. Novartis Recent Development
Table 54. UCB Company Details
Table 55. UCB Business Overview
Table 56. UCB Anti-Rheumatic Drugs Product
Table 57. UCB Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 58. UCB Recent Development
Table 59. AbbVie Company Details
Table 60. AbbVie Business Overview
Table 61. AbbVie Anti-Rheumatic Drugs Product
Table 62. AbbVie Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 63. AbbVie Recent Development
Table 64. Bristol-Myers Squibb Company Details
Table 65. Bristol-Myers Squibb Business Overview
Table 66. Bristol-Myers Squibb Anti-Rheumatic Drugs Product
Table 67. Bristol-Myers Squibb Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 68. Bristol-Myers Squibb Recent Development
Table 69. Merck Company Details
Table 70. Merck Business Overview
Table 71. Merck Anti-Rheumatic Drugs Product
Table 72. Merck Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 73. Merck Recent Development
Table 74. HEYL Chemisch-pharmazeutische Fabrik Company Details
Table 75. HEYL Chemisch-pharmazeutische Fabrik Business Overview
Table 76. HEYL Chemisch-pharmazeutische Fabrik Anti-Rheumatic Drugs Product
Table 77. HEYL Chemisch-pharmazeutische Fabrik Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 78. HEYL Chemisch-pharmazeutische Fabrik Recent Development
Table 79. Roche Company Details
Table 80. Roche Business Overview
Table 81. Roche Anti-Rheumatic Drugs Product
Table 82. Roche Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 83. Roche Recent Development
Table 84. Johnson & Johnson Company Details
Table 85. Johnson & Johnson Business Overview
Table 86. Johnson & Johnson Anti-Rheumatic Drugs Product
Table 87. Johnson & Johnson Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 88. Johnson & Johnson Recent Development
Table 89. Amgen Company Details
Table 90. Amgen Business Overview
Table 91. Amgen Anti-Rheumatic Drugs Product
Table 92. Amgen Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 93. Amgen Recent Development
Table 94. Pfizer Company Details
Table 95. Pfizer Business Overview
Table 96. Pfizer Anti-Rheumatic Drugs Product
Table 97. Pfizer Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 98. Pfizer Recent Development
Table 99. GSK Company Details
Table 100. GSK Business Overview
Table 101. GSK Anti-Rheumatic Drugs Product
Table 102. GSK Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 103. GSK Recent Development
Table 104. Sanofi Company Details
Table 105. Sanofi Business Overview
Table 106. Sanofi Anti-Rheumatic Drugs Product
Table 107. Sanofi Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 108. Sanofi Recent Development
Table 109. Abbott Laboratories Company Details
Table 110. Abbott Laboratories Business Overview
Table 111. Abbott Laboratories Anti-Rheumatic Drugs Product
Table 112. Abbott Laboratories Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 113. Abbott Laboratories Recent Development
Table 114. Teva Pharmaceutical Company Details
Table 115. Teva Pharmaceutical Business Overview
Table 116. Teva Pharmaceutical Anti-Rheumatic Drugs Product
Table 117. Teva Pharmaceutical Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 118. Teva Pharmaceutical Recent Development
Table 119. Eli Lilly and Company Company Details
Table 120. Eli Lilly and Company Business Overview
Table 121. Eli Lilly and Company Anti-Rheumatic Drugs Product
Table 122. Eli Lilly and Company Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 123. Eli Lilly and Company Recent Development
Table 124. Celltrion Company Details
Table 125. Celltrion Business Overview
Table 126. Celltrion Anti-Rheumatic Drugs Product
Table 127. Celltrion Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 128. Celltrion Recent Development
Table 129. Astellas Pharma Company Details
Table 130. Astellas Pharma Business Overview
Table 131. Astellas Pharma Anti-Rheumatic Drugs Product
Table 132. Astellas Pharma Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 133. Astellas Pharma Recent Development
Table 134. Simcere Company Details
Table 135. Simcere Business Overview
Table 136. Simcere Anti-Rheumatic Drugs Product
Table 137. Simcere Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 138. Simcere Recent Development
Table 139. Daiichi Sankyo Company Details
Table 140. Daiichi Sankyo Business Overview
Table 141. Daiichi Sankyo Anti-Rheumatic Drugs Product
Table 142. Daiichi Sankyo Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 143. Daiichi Sankyo Recent Development
Table 144. Asahi Kasei Company Details
Table 145. Asahi Kasei Business Overview
Table 146. Asahi Kasei Anti-Rheumatic Drugs Product
Table 147. Asahi Kasei Revenue in Anti-Rheumatic Drugs Business (2019-2024) & (US$ Million)
Table 148. Asahi Kasei Recent Development
Table 149. Research Programs/Design for This Report
Table 150. Key Data Information from Secondary Sources
Table 151. Key Data Information from Primary Sources
Table 152. Authors List of This Report
List of Figures
Figure 1. Anti-Rheumatic Drugs Picture
Figure 2. Global Anti-Rheumatic Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Anti-Rheumatic Drugs Market Share by Type: 2023 VS 2030
Figure 4. Disease Modifying Anti-rheumatics Drugs (DMARD's) Features
Figure 5. Nonsteroidal Anti-inflammatory Drugs (NSAID's) Features
Figure 6. Corticosteroids Features
Figure 7. Uric Acid Drugs Features
Figure 8. Others Features
Figure 9. Global Anti-Rheumatic Drugs Market Size by Application (2024-2030) & (US$ Million)
Figure 10. Global Anti-Rheumatic Drugs Market Share by Application: 2023 VS 2030
Figure 11. Hospital Pharmacies Case Studies
Figure 12. Retail Pharmacies Case Studies
Figure 13. Online Pharmacies Case Studies
Figure 14. Anti-Rheumatic Drugs Report Years Considered
Figure 15. Global Anti-Rheumatic Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 16. Global Anti-Rheumatic Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 17. Global Anti-Rheumatic Drugs Market Share by Region: 2023 VS 2030
Figure 18. Global Anti-Rheumatic Drugs Market Share by Players in 2023
Figure 19. Global Top Anti-Rheumatic Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Rheumatic Drugs as of 2023)
Figure 20. The Top 10 and 5 Players Market Share by Anti-Rheumatic Drugs Revenue in 2023
Figure 21. North America Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. North America Anti-Rheumatic Drugs Market Share by Country (2019-2030)
Figure 23. United States Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Canada Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. Europe Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Europe Anti-Rheumatic Drugs Market Share by Country (2019-2030)
Figure 27. Germany Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. France Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. U.K. Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Italy Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Russia Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Nordic Countries Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Asia-Pacific Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Asia-Pacific Anti-Rheumatic Drugs Market Share by Region (2019-2030)
Figure 35. China Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Japan Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. South Korea Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Southeast Asia Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. India Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Australia Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Latin America Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Latin America Anti-Rheumatic Drugs Market Share by Country (2019-2030)
Figure 43. Mexico Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Brazil Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Middle East & Africa Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Middle East & Africa Anti-Rheumatic Drugs Market Share by Country (2019-2030)
Figure 47. Turkey Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 48. Saudi Arabia Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 49. UAE Anti-Rheumatic Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 50. Novartis Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 51. UCB Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 52. AbbVie Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 53. Bristol-Myers Squibb Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 54. Merck Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 55. HEYL Chemisch-pharmazeutische Fabrik Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 56. Roche Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 57. Johnson & Johnson Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 58. Amgen Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 59. Pfizer Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 60. GSK Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 61. Sanofi Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 62. Abbott Laboratories Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 63. Teva Pharmaceutical Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 64. Eli Lilly and Company Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 65. Celltrion Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 66. Astellas Pharma Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 67. Simcere Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 68. Daiichi Sankyo Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 69. Asahi Kasei Revenue Growth Rate in Anti-Rheumatic Drugs Business (2019-2024)
Figure 70. Bottom-up and Top-down Approaches for This Report
Figure 71. Data Triangulation
Figure 72. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
